AstraZeneca Advances Prostate Cancer Pipeline With New ANDROMEDA Trial on AZD9750

AstraZeneca (AZN) announced an update on their ongoing clinical study.

Study Overview
The ANDROMEDA trial is a Phase I/II study run by AstraZeneca to test a new prostate cancer drug called AZD9750 in men with metastatic disease. Officially titled “A Phase I/II, Modular, Open-Label, Multi-Centre Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD9750 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Metastatic Prostate Cancer (ANDROMEDA),” the trial aims to find a safe dose, understand how the drug behaves in the body, and get an early read on how well it works. For investors, this is an early but important step in expanding AstraZeneca’s oncology portfolio into advanced prostate cancer, an area with high unmet need and strong commercial potential.

Intervention/Treatment
The study tests AZD9750, an oral cancer drug designed to target the androgen receptor pathway, a key driver of prostate cancer growth. It is being studied both alone and in combination with saruparib (AZD5305), a selective PARP1 inhibitor from AstraZeneca’s existing pipeline. On its own, AZD9750 aims to block cancer growth by degrading a crucial hormone-driven signal; in combination, the goal is to create a stronger, more durable response in tumors that rely on DNA repair pathways, potentially broadening the addressable patient population.

Study Design
This is an interventional, first-in-human trial with several parts that follow one another. Some parts are randomized, but many are not, reflecting the exploratory nature of an early-stage cancer study. There is no placebo and no blinding; both doctors and patients know which treatment is being given. The trial starts with small groups to find a safe dose, then moves into larger groups to fine-tune the dose and check how well the drug controls cancer. The primary goal is treatment-focused: to see if AZD9750, alone or with saruparib, can be given safely while showing enough early benefit to justify larger, later-stage trials.

Study Timeline
The study was first submitted on December 19, 2025, marking its formal entry into the clinical pipeline. The trial status is “not yet recruiting,” meaning sites are being set up and patients have not started treatment. The latest update to the record was filed on January 12, 2026, indicating active operational progress before first patient dosing. Primary completion and final completion dates are not yet posted, which is typical for a complex modular early-phase cancer study and underlines that investors are still in a long lead time before any pivotal readout or regulatory event.

Market Implications
For AstraZeneca shareholders, ANDROMEDA is an early but strategic signal. It adds a new mechanism, AZD9750, to the company’s already strong oncology platform, and it leverages internal assets like saruparib to build combination franchises. Success here could expand AstraZeneca’s footprint in prostate cancer, a market dominated today by players such as Johnson & Johnson, Pfizer/Astellas, and Bayer. In the near term, this update is unlikely to move AZN’s share price on its own because it is a pre-revenue, early-stage asset with no efficacy data yet. However, the launch of a first-in-human study can support the medium-term growth story by reinforcing pipeline depth and management’s commitment to next-generation targeted therapies. For sector investors, the trial highlights ongoing competition around androgen receptor and DNA damage pathways, and any future positive signals from ANDROMEDA could pressure incumbents in the metastatic prostate cancer space while boosting sentiment toward AZN’s long-term oncology valuation.

The ANDROMEDA study is active at the setup stage and recently updated, with further details available on the ClinicalTrials portal.

To learn more about AZN’s potential, visit the AstraZeneca drug pipeline page.